Loredana Regep

Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a

Vincent Rijckborst, Bettina E. Hansen, Péter Ferenci et al. · Journal of Hepatology · 2012 · 170 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +10

Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B

Pietro Lampertico, Mauro Viganò, G.G. Di Costanzo et al. · Gut · 2012 · 117 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: On-treatment kinetics of HBsAg serum levels vary by HBV genotype

Maurizia Rossana Brunetto, Patrick Marcellin, B. Cherubini et al. · Journal of Hepatology · 2013 · 93 citations

Pharmacy, Pharmacokinetics, Pharmacotherapy +13

The prevalence and risk factors of hepatitis C virus infection in adult population in Romania: a nationwide survey 2006 - 2008.

Liana Gheorghe, Irma Eva Csiki, Speranţa Iacob et al. · PubMed · 2010 · 91 citations

Veterinary Medicine, Infectious Diseases, Epidemiology +15

Pregnancy and Fetal Outcomes After Exposure to Mefloquine in the Pre- and Periconception Period and During Pregnancy

Patricia Schlagenhauf, William A. Blumentals, P. M. Suter et al. · Clinical Infectious Diseases · 2012 · 59 citations · Full text

Medicine, Maternal Health, Obstetrics +17